HOME >> MEDICINE >> NEWS
ENBREL (Etanercept) Receives FDA Approval For Treatment Of Juvenile Rheumatoid Arthritis

Therapeutic Breakthrough For Rheumatoid Arthritis Becomes First Biologic Response Modifier Approved To Treat Children And Teen-Agers With JRA

SEATTLE - ENBREL® (etanercept) was approved today by the U.S. Food and Drug Administration (FDA) for the treatment of moderately to severely active polyarticular-course juvenile rheumatoid arthritis (JRA) in patients who have had an inadequate response to one or more disease modifying medicines. Today's announcement was made by Immunex Corporation (NASDAQ: IMNX) and Wyeth-Ayerst Pharmaceuticals, a division of American Home Products Corporation (NYSE: AHP), the companies who market ENBREL in North America.

JRA is an autoimmune system disease that strikes children before age sixteen and can cause painful joint swelling, deformity, stunted growth and increased mortality. According to the Arthritis Foundation, JRA affects approximately 50,000 children in the United States. The disease can impair a child's ability to take part in physical activities, make daily activities such as schoolwork more difficult, and affect a child's physical appearance.

"I never thought my daughter would be able to get out of bed in the morning without experiencing extreme pain, much less attend school with her peers on a daily basis," said Erite Freed, the mother of a 15-year-old girl, Lauren Blumenthal, with JRA who participated in the ENBREL JRA clinical trial. "ENBREL has had a dramatic effect on my daughter's life."

"Children with JRA face the possibility of a lifetime of pain and disability," said Daniel J. Lovell, M.D., M.P.H., a pediatric rheumatologist at Children's Hospital Medical Center of Cincinnati and principal investigator of the clinical study on which the JRA indication was based. "Rheumatologists have had limited options to treat children with moderate to severe arthritis. The approval of ENBREL for JRA opens a new era of hope for these children, teen-agers and the
'"/>

Contact: Tim Warner
warnert@immunex.com
206-470-4193
Immunex Corporation
28-May-1999


Page: 1 2 3 4

Related medicine news :

1. ENBREL (etanercept) long-term clinical trial data
2. ENBREL application for early, active rheumatoid arthritis filed with the U.S. Food and Drug Administration
3. Circulation publishes phase I study of ENBREL in patients with chronic heart failure
4. Positive Results Of Pivotal Phase III Trial With ENBREL In Patients With Early, Active Rheumatoid Arthritis
5. ENBREL (Etanercept) Patient And Physician Support Web Site Launched
6. ENBREL Phase III Data Published In Annals Of Internal Medicine
7. Emory Receives $14 Million Federal Grant To Coordinate 50-Site Brain Attack Prevention Trial
8. Cedars-Sinai Medical Center Nursing Administrator Receives Nursing Excellence Award
9. UK Allied Health Professor Receives Patent On Using Lithium With AIDS Drugs
10. UCSF AIDS Research Center Receives Major New Grant From NIH
11. UT Southwestern Receives FDA Grant To Continue Studies Of Cancer-Fighting Drug Not Used For Past 50 Years

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/31/2020)... Ga. (PRWEB) , ... August 31, 2020 , ... The pandemic and topsy-turvy economic outlook ... examine our budgets and look for ways to trim the fat from our monthly expenses ... your finances, but it’s also important that you have a financial safety net in place ...
(Date:8/31/2020)... ... August 31, 2020 , ... Dr. ... with persons with autism and other developmental disabilities, as well as supporting staff ... education, adolescents with autism, school consultation, and staff development. She joined the company ...
(Date:8/28/2020)... (PRWEB) , ... August 28, 2020 , ... ... Founder & CEO Craig Mandeville was named an Entrepreneur Of The Year® 2020 ... program honors entrepreneurial business leaders whose ambitions deliver innovation, growth and prosperity as ...
(Date:8/28/2020)... GROVE, Ill. (PRWEB) , ... August 28, 2020 ... ... COVID-19, The Nourished Group set out to continue helping the specialty-diet ... attendees can discover new gluten-free products, get coupons, enter giveaways, chat with brands ...
(Date:8/28/2020)... (PRWEB) , ... August 28, 2020 , ... ... international observations that strongly suggest that obese individuals are at an increased risk ... are any more likely to catch COVID-19; however, because the same organ systems ...
Breaking Medicine News(10 mins):
(Date:8/27/2020)... (PRWEB) , ... August 27, 2020 , ... ... analytics, has partnered with Enquire, a leading provider of cloud CRM, marketing automation, ... two organizations' strategic partnership will involve the integration of Trella’s performance intelligence data ...
(Date:8/27/2020)... ... August 27, 2020 , ... The GHT Companies , a leading ... for Feeding San Diego with a press conference at its manufacturing facility ... final check of $5,000.00+ representing an overall donation result exceeding $30,000 to Feeding San ...
(Date:8/26/2020)... ... August 26, 2020 , ... AseptiScope, a privately funded San ... of the Year by MedTech Outlook. , “AseptiScope is pleased to receive ... time, clinicians who wear gloves on their hands, goggles on their eyes, covers on ...
Breaking Medicine Technology:
Cached News: